Finding 1078601 (2020-002)

Material Weakness Repeat Finding
Requirement
P
Questioned Costs
-
Year
2020
Accepted
2024-10-10

AI Summary

  • Core Issue: Lack of proper segregation of duties in financial processes, allowing one individual excessive control over transactions.
  • Impacted Requirements: Non-compliance with 2 CFR 200.303, which mandates effective internal controls for managing federal awards.
  • Recommended Follow-Up: Implement training for finance staff, segregate payment initiation and authorization, and assign mail handling to an employee outside the finance department.

Finding Text

Finding 2020-002: Segregation of Duties Federal Program: Research and Development Cluster (Education and Human Resources) Assistance Listing Number and Title: 47.076 STEM Education Name of Federal Agency, Pass Through Entity (when applicable), Award Number and Year: National Science Foundation: 1431638 (9/1/2014 – 8/31/2022), 1524963 (11/1/2015 – 9/30/2021), 1500529 (9/1/2015 – 8/31/2022), 1624185 (9/16/2016 – 8/31/2022), 1640791 (9/15/2016 – 8/31/2022), 1720869 (5/15/2017 – 4/30/2022), 1726113 (8/1/2017 – 9/30/2023), 1645003 (3/15/2017 – 2/29/2020), 1821462 (7/1/2018 – 6/30/2024), 1812860 (9/1/2018 – 8/31/2020), 1940925 (1/15/2020 – 12/31/2023), 1907950 (7/1/2019 – 6/30/2024), 2015205 (4/1/2020 – 3/31/2022), 2021059 (10/1/2020 – 9/30/2024) Federal Program: Research and Development Cluster (Mathematical and Physical Sciences) Assistance Listing Number and Title: 47.049 Mathematical and Physical Sciences Name of Federal Agency, Pass Through Entity, Award Number and Year: National Science Foundation: 1821372 (10/1/2018 – 9/30/2024 pass through entity American Physical Society), 1834530 (9/1/2018 – 8/31/2025 pass through entity American Physical Society), 1938815 (8/1/2020 – 7/31/2024) Federal Program: Research and Development Cluster (Science) Assistance Listing Number and Title: 43.001 Science Name of Federal Agency, Pass Through Entity: NNX16AR36A (8/24/2016 – 8/23/2021 pass through entity Temple University of the Commonwealth System of Higher Education) Material Weakness in Internal Controls Over Compliance, Other matters Criteria or Specific Requirement (Including Statutory, Regulatory, or Other Citation): As noted in 2 CFR 200.303 “The non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).” Condition: The Chief Financial Officer is responsible for posting entries into the accounting system without a second level review, and obtaining all bank statements unopened while also having the ability to add or modify payees and unilaterally initiate and authorize electronic fund transfers such as automated clearing house payments. The CFO is also responsible for opening the mail which may contain payments by check, and can manually reduce receivable balances. Cause: Accounting department employees have not been trained to perform tasks that would allow for a proper segregation of duties related to accounting entries. Employees outside of the accounting department are permitted to work from home, which limits the employees who can perform functions such as opening the mail. Effect or Potential Effect: If any one employee can control all stages of a transaction, defalcations or irregularities could occur and not be detected timely. Questioned Costs: None noted. Identification as a Repeat Finding, if Applicable: 2019-001 Recommendation: We recommend that AAPT provide training to the Finance and Administration staff so that entries can be subject to supervisory review by an individual knowledgeable as to the propriety of the entries. We recommend that AAPT segregate the ability to initiate and authorize electronic payments. We recommend that an employee outside of the Finance and Administration department open the AAPT mail and create an initial recordation log of checks or cash received. Views of Responsible Officials and Planned Corrective Actions: AAPT has instituted the segregation of duties of submitting and approval of electronic payments. The senior accountant has been authorized to submit the ACH/Wire transfer requests. The CFO has the authorization of approval of submitted electronic payments. The change was activated around March 15, 2024 The staff will be trained on generating journal entries previous prepared by the CFO and supervised and approve by the CFO – completed date May 15, 2024 The administrative assistant of the CEO will come to AAPT twice weekly to process incoming mail and create an initial recordation log of checks or cash received. The administrative assistant will not have access in any system to enter/modify/delete any information related to checks that are received. Anticipated Completion Date: January 2025 Responsible Official: Michael Brosnan, CFO

Categories

Internal Control / Segregation of Duties Material Weakness Matching / Level of Effort / Earmarking

Other Findings in this Audit

  • 502144 2020-001
    Significant Deficiency
  • 502145 2020-002
    Material Weakness Repeat
  • 502146 2020-005
    Significant Deficiency Repeat
  • 502147 2020-001
    Significant Deficiency
  • 502148 2020-002
    Material Weakness Repeat
  • 502149 2020-005
    Significant Deficiency Repeat
  • 502150 2020-001
    Significant Deficiency
  • 502151 2020-002
    Material Weakness Repeat
  • 502152 2020-004
    Significant Deficiency
  • 502153 2020-005
    Significant Deficiency Repeat
  • 502154 2020-001
    Significant Deficiency
  • 502155 2020-002
    Material Weakness Repeat
  • 502156 2020-004
    Significant Deficiency
  • 502157 2020-005
    Significant Deficiency Repeat
  • 502158 2020-001
    Significant Deficiency
  • 502159 2020-002
    Material Weakness Repeat
  • 502160 2020-005
    Significant Deficiency Repeat
  • 502161 2020-006
    Significant Deficiency Repeat
  • 502162 2020-001
    Significant Deficiency
  • 502163 2020-002
    Material Weakness Repeat
  • 502164 2020-005
    Significant Deficiency Repeat
  • 502165 2020-001
    Significant Deficiency
  • 502166 2020-002
    Material Weakness Repeat
  • 502167 2020-004
    Significant Deficiency
  • 502168 2020-005
    Significant Deficiency Repeat
  • 502169 2020-001
    Significant Deficiency
  • 502170 2020-002
    Material Weakness Repeat
  • 502171 2020-005
    Significant Deficiency Repeat
  • 502172 2020-001
    Significant Deficiency
  • 502173 2020-002
    Material Weakness Repeat
  • 502174 2020-005
    Significant Deficiency Repeat
  • 502175 2020-001
    Significant Deficiency
  • 502176 2020-002
    Material Weakness Repeat
  • 502177 2020-003
    Material Weakness Repeat
  • 502178 2020-005
    Significant Deficiency Repeat
  • 502179 2020-001
    Significant Deficiency
  • 502180 2020-002
    Material Weakness Repeat
  • 502181 2020-003
    Material Weakness Repeat
  • 502182 2020-005
    Significant Deficiency Repeat
  • 502183 2020-001
    Significant Deficiency
  • 502184 2020-002
    Material Weakness Repeat
  • 502185 2020-005
    Significant Deficiency Repeat
  • 502186 2020-001
    Significant Deficiency
  • 502187 2020-002
    Material Weakness Repeat
  • 502188 2020-005
    Significant Deficiency Repeat
  • 502189 2020-001
    Significant Deficiency
  • 502190 2020-002
    Material Weakness Repeat
  • 502191 2020-005
    Significant Deficiency Repeat
  • 502192 2020-001
    Significant Deficiency
  • 502193 2020-002
    Material Weakness Repeat
  • 502194 2020-005
    Significant Deficiency Repeat
  • 502195 2020-001
    Significant Deficiency
  • 502196 2020-002
    Material Weakness Repeat
  • 502197 2020-005
    Significant Deficiency Repeat
  • 502198 2020-001
    Significant Deficiency
  • 502199 2020-002
    Material Weakness Repeat
  • 502200 2020-005
    Significant Deficiency Repeat
  • 502201 2020-001
    Significant Deficiency
  • 502202 2020-002
    Material Weakness Repeat
  • 502203 2020-005
    Significant Deficiency Repeat
  • 1078586 2020-001
    Significant Deficiency
  • 1078587 2020-002
    Material Weakness Repeat
  • 1078588 2020-005
    Significant Deficiency Repeat
  • 1078589 2020-001
    Significant Deficiency
  • 1078590 2020-002
    Material Weakness Repeat
  • 1078591 2020-005
    Significant Deficiency Repeat
  • 1078592 2020-001
    Significant Deficiency
  • 1078593 2020-002
    Material Weakness Repeat
  • 1078594 2020-004
    Significant Deficiency
  • 1078595 2020-005
    Significant Deficiency Repeat
  • 1078596 2020-001
    Significant Deficiency
  • 1078597 2020-002
    Material Weakness Repeat
  • 1078598 2020-004
    Significant Deficiency
  • 1078599 2020-005
    Significant Deficiency Repeat
  • 1078600 2020-001
    Significant Deficiency
  • 1078602 2020-005
    Significant Deficiency Repeat
  • 1078603 2020-006
    Significant Deficiency Repeat
  • 1078604 2020-001
    Significant Deficiency
  • 1078605 2020-002
    Material Weakness Repeat
  • 1078606 2020-005
    Significant Deficiency Repeat
  • 1078607 2020-001
    Significant Deficiency
  • 1078608 2020-002
    Material Weakness Repeat
  • 1078609 2020-004
    Significant Deficiency
  • 1078610 2020-005
    Significant Deficiency Repeat
  • 1078611 2020-001
    Significant Deficiency
  • 1078612 2020-002
    Material Weakness Repeat
  • 1078613 2020-005
    Significant Deficiency Repeat
  • 1078614 2020-001
    Significant Deficiency
  • 1078615 2020-002
    Material Weakness Repeat
  • 1078616 2020-005
    Significant Deficiency Repeat
  • 1078617 2020-001
    Significant Deficiency
  • 1078618 2020-002
    Material Weakness Repeat
  • 1078619 2020-003
    Material Weakness Repeat
  • 1078620 2020-005
    Significant Deficiency Repeat
  • 1078621 2020-001
    Significant Deficiency
  • 1078622 2020-002
    Material Weakness Repeat
  • 1078623 2020-003
    Material Weakness Repeat
  • 1078624 2020-005
    Significant Deficiency Repeat
  • 1078625 2020-001
    Significant Deficiency
  • 1078626 2020-002
    Material Weakness Repeat
  • 1078627 2020-005
    Significant Deficiency Repeat
  • 1078628 2020-001
    Significant Deficiency
  • 1078629 2020-002
    Material Weakness Repeat
  • 1078630 2020-005
    Significant Deficiency Repeat
  • 1078631 2020-001
    Significant Deficiency
  • 1078632 2020-002
    Material Weakness Repeat
  • 1078633 2020-005
    Significant Deficiency Repeat
  • 1078634 2020-001
    Significant Deficiency
  • 1078635 2020-002
    Material Weakness Repeat
  • 1078636 2020-005
    Significant Deficiency Repeat
  • 1078637 2020-001
    Significant Deficiency
  • 1078638 2020-002
    Material Weakness Repeat
  • 1078639 2020-005
    Significant Deficiency Repeat
  • 1078640 2020-001
    Significant Deficiency
  • 1078641 2020-002
    Material Weakness Repeat
  • 1078642 2020-005
    Significant Deficiency Repeat
  • 1078643 2020-001
    Significant Deficiency
  • 1078644 2020-002
    Material Weakness Repeat
  • 1078645 2020-005
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
47.049 Mathematical and Physical Sciences $10,562
47.076 Education and Human Resources $6,442
43.001 Science $4,172